Bard Associates’s Biofrontera BFRIW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.92K Hold
154,900
﹤0.01% 223
2025
Q4
$13.9K Hold
154,900
﹤0.01% 201
2025
Q3
$15K Hold
154,900
﹤0.01% 157
2025
Q2
$16.3K Sell
154,900
-25,000
-14% -$2.11K 0.01% 169
2025
Q1
$11K Hold
179,900
﹤0.01% 175
2024
Q4
$10.9K Hold
179,900
﹤0.01% 177
2024
Q3
$4.16K Hold
179,900
﹤0.01% 173
2024
Q2
$6.32K Sell
179,900
-4,000
-2% -$204 ﹤0.01% 168
2024
Q1
$12.4K Sell
183,900
-4,000
-2% -$118 ﹤0.01% 173
2023
Q4
$1.88K Sell
187,900
-13,000
-6% -$324 ﹤0.01% 172
2023
Q3
$6.05K Sell
200,900
-100
-0% -$9 ﹤0.01% 183
2023
Q2
$22.1K Hold
201,000
0.01% 180
2023
Q1
$49.2K Hold
201,000
0.02% 180
2022
Q4
$40.4K Hold
201,000
0.02% 185
2022
Q3
$71K Hold
201,000
0.03% 175
2022
Q2
$143K Buy
201,000
+5,000
+3% +$5.51K 0.06% 164
2022
Q1
$286K Sell
196,000
-14,100
-7% -$19.6K 0.1% 151
2021
Q4
$756K Buy
+210,100
New +$453K 0.25% 116

Other funds holding BFRIW

Bard Associates's BFRIW Position: Q1 2026 in Review

Bard Associates held its Biofrontera (BFRIW) position steady in Q1 2026 at 154,900 shares worth $5.92K. The position accounts for ﹤0.01% of the portfolio, ranked #223.

Bard Associates first reported a position in BFRIW in Q4 2021 and has held it in 18 quarters since. The position peaked at $756K in Q4 2021. 6 funds tracked by Wall St. Rank hold BFRIW as of Q1 2026.

  • Bard Associates held 154,900 shares of Biofrontera worth $5.92K as of Q1 2026.
  • Bard Associates left its Biofrontera share count unchanged in Q1 2026.
  • Biofrontera made up ﹤0.01% of Bard Associates's portfolio in Q1 2026, its #223 holding.
  • Bard Associates first reported a position in Biofrontera in Q4 2021 and has held it in 18 quarters since.
  • Bard Associates's Biofrontera position peaked at $756K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Biofrontera as of Q1 2026.

Based on Bard Associates's 13F filing for Q1 2026, filed 8 May 2026.